LENZ Therapeutics, Inc.
LENZHealthcare|Biotechnology|US
$3.50
+0.49 (+16.28%)
DCF Value
$2.33
Tangible Book / Share
$6.11
Cash / Share
$6.28
About
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Stock Price
-84.8%(1Y)
1M
-0.8%
3M
-34.7%
6M
-65.2%
YTD
-78.1%
1Y
-84.9%
3Y
-68.8%
5Y
-94.2%
Pipeline Summary
11 total trials2
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
Completed: 10Recruiting: 1
Active Trials (1)
Effects of Neoadjuvant Prehabilitation on Post-Interventional Physical and Psychological Outcomes in Oncology Patients With Solid Tumors
NCT07464457Breast Cancer
N/ARecruiting
Enrollment: 125 participants
Key Facts
Market Cap$110.0M
Employees152 (+262% YoY)
CEOEvert Schimmelpennink
IPO DateJun 25, 2021
Beta1.73
52-Week Range$2.8 – $32.13
Avg Volume924,588
ExchangeNASDAQ
Websitelenz-tx.com
Ownership
Float86.5%
Shares Outstanding31.4M
Recent Insider Trades
Chevallard Daniel R.AWARD
Oct 30, 2026652,063 shares @ $3.05
RA CAPITAL MANAGEMENT, L.P.SELL
Oct 29, 20262,159,516 shares @ $3.36
RA CAPITAL MANAGEMENT, L.P.SELL
Oct 29, 2026451,998 shares @ $3.36
RA CAPITAL MANAGEMENT, L.P.SELL
Oct 29, 2026107,170 shares @ $3.36
RA CAPITAL MANAGEMENT, L.P.AWARD
Jun 15, 202622,100 shares @ $6.63
Peers
Recent News
LENZ Therapeutics, Inc. (LENZ) Q3 2026 Earnings Call Transcript
Oct 29, 2026 · seekingalpha.com
LENZ Therapeutics Q3 Earnings Call Highlights
Oct 29, 2026 · marketbeat.com
LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates
Oct 28, 2026 · zacks.com
LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession
Oct 28, 2026 · globenewswire.com
LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
Oct 22, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:19 AM